© 2022 Biopharma

A private equity (PE) investor was considering A transaction in a young biopharma
that develops a novel diagnostic kit for the early detection of selected cancer indications. The PE
investor hired BIM to conduct A brief technological, patent and market DD.

BIM's team reviewed the contents of an online data room and conducted online
interviews with the management team. While no major technological red flags were identified,
our team concluded that the competition in the field vis-à-vis the time frame and budget needed
to reach value inflecting milestones makes the investment less attractive. The PE investor used
BIM's output and decided not to proceed with the investment.

Made on